Brief: Hyloris Out-Licensed Its ADHD Treatment Candidate In Canada To Kye Pharmaceuticals

Hyloris Pharmaceuticals SA

24/10/2023 06:05

Oct 24 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * HYLORIS PHARMACEUTICALS ANNOUNCES IT HAS OUT-LICENSED ITS
PRODUCT CANDIDATE ATOMOXETINE ORAL LIQUID FOR TREATMENT OF
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CANADA TO KYE
PHARMACEUTICALS
    * KYE PHARMACEUTICALS TO REGISTER AND COMMERCIALIZE IN
CANADA
    * KYE PHARMACEUTICALS IS TARGETING A REGULATORY SUBMISSION
IN 2024
    * TERRITORIAL EXPANSION FOR ATOMOXETINE ORAL LIQUID SHOULD
NOT
RESULT IN ADDITIONAL PRODUCT-RELATED INVESTMENTS FOR HYLORIS

Source text for Eikon:  urn:newsml:reuters.com:*:nGNE4l5DyP
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))